Professor and Director of Pharmaceutical Outcomes Research and Policy Program, Department of Pharmacy; Auxiliary Member, Institute for Public Health Genetics, University of Washington; Affiliate Investigator, Public Health Sciences Division, Fred Hutchinson Cancer Research Center
PharmD, University of California, San Francisco; PhD in Pharmaceutical Chemistry, University of California, San Francisco; Bachelor of Science in Chemistry, University of California, Santa Barbara
- Cost effectiveness modeling in pharmaceutical outcomes
- Pharmacogenomic-based drug therapies
- Pharm 520: Introduction to Pharmacoeconomics & Outcomes Research
- Pharm 534: Economic Evaluation in Health & Medicine
- Pharm 535/Hserv 584: Evaluating Cost & Outcomes in Health & Medicine
- Pharm 597: Graduate Seminar
Dr. Veenstra is a Professor in the Pharmaceutical Outcomes Research and Policy Program in the Department of Pharmacy, and a member of the Institute for Public Health Genetics at the University of Washington in Seattle. He graduated from the University of California San Francisco, with doctoral degrees in clinical pharmacy and computational chemistry. He conducted his postdoctoral training in health economics and outcomes research with the University of Washington, including a one-year externship with Roche Global Pharmacoeconomics.
Dr. Veenstra's primary research interests are the clinical, economic, and policy implications of using genomic information in healthcare. His major research projects include evaluation of pharmacogenomics in diverse populations, decision modeling to inform research prioritization and stakeholder decision-making in oncology, and evaluation of the clinical, economic, and personal utility of whole genome sequencing.
Dr. Veenstra's research has been funded through grants from the Centers for Disease Control, National Cancer Institute, National Human Genome Research Institute, and the National Institute for General Medical Sciences. Dr. Veenstra is a past member of EGAPP, a CDC-sponsored evidence-based recommendation group for genomic tests, and is a current member of the Institute of Medicine (IOM) Roundtable on Translating Genomic-Based Research for Health.
Dr. Veenstra's other major research interest is the development of disease simulation, risk-benefit, and cost-effectiveness models. He has worked extensively with the Academy of Managed Care Pharmacy (AMCP) to develop guidelines and train decision makers in the practical application of cost-effectiveness models. Dr. Veenstra is an author or co-author of over 100 peer-reviewed publications and five book chapters.
Dr. Veenstra is a member of the Institute for Public Health Genetics at UW, the International Society for Pharmacoeconomics and Outcomes Research, and the International Health Economics Association. Dr. Veenstra is a past recipient of the PhRMA Foundation Career Development Award in Pharmacoeconomics.
View Selected Publications